Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: Two randomized trials

Current Medical Research and Opinion

Volumn 27, Issue 6, 2011, Pages 1243-1253

  Hochberg, Marc C ^a   Fort, John G ^b   Svensson, Ola ^c   Hwang, Clara ^d   Sostek, Mark ^d  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b POZEN Inc   (United States)

^c ASTRAZENECA R AND D   (Sweden)

^d ASTRAZENECA   (United Kingdom)

Author keywords

COX inhibitors; Esomeprazole magnesium; Naproxen; Non inferiority; Nonsteroidal anti inflammatory drugs (NSAIDs); Osteoarthritis

Indexed keywords

CELECOXIB; ESOMEPRAZOLE; NAPROXEN; PARACETAMOL; PLACEBO;

ADULT; ARTHRALGIA; ARTICLE; CANADA; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG RELEASE; DYSPEPSIA; ENTERIC COATED TABLET; FEMALE; HEADACHE; HUMAN; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; VISUAL ANALOG SCALE;

DOUBLE-BLIND METHOD; DRUG COMBINATIONS; HUMANS; NAPROXEN; OMEPRAZOLE; OSTEOARTHRITIS, KNEE; PLACEBOS; PYRAZOLES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 79956134847     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.580340     Document Type: Article

References (46)

1. Altman R, Hochberg MC, Moskowitz RW, et al. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000;43:1905-15
2. Desai SP, Solomon DH, Abramson SP, et al. Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper. Arthritis Rheum 2008;59:1058-73
3. National Institute for Health and Clinical Excellence. The care and management of osteoarthritis in adults. NICE clinical guideline 59. Available at: http://www.nice.org.uk/nicemedia/pdf/CG59NICEguideline.pdf [Last accessed 17 Dec 2010]
4. Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005;64:669-81 (Pubitemid 40559291)
5. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137-62 (Pubitemid 351222155)
6. Garcia Rodriguez LA, Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 2007;132:498-506 (Pubitemid 46274667)
7. Lanas A, Perez-Aisa MA, Feu F, et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005;100:1685-93 (Pubitemid 41648418)
8. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120:594-606 (Pubitemid 32171634)
9. Scheiman JM, Fendrick AM. Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs. Arthritis Res Ther 2005;7(Suppl. 4):S23-S29 (Pubitemid 41646251)
10. Straus WL, Ofman JJ, MacLean C, et al. Do NSAIDs cause dyspepsia? A meta-analysis evaluating alternative dyspepsia definitions. Am J Gastroenterol 2002;97:1951-8
11. Chen Y-F, Jobanputra P, Barton P, et al. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008;12:1-278, iii
12. Chou R, Helfand M, Peterson K, et al. Drug class review of cyclo-oxygenase (C0X)-2 inhibitors and non-steroidal anti-inflammatory drugs (NSAIDs).Final report. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20496448 [Last accessed 2 Jul 2010]
13. Chou R, Helfand M, Peterson K, et al. Comparative effectiveness and safety of analgesics for osteoarthritis: comparative effectiveness review: Agency for Healthcare Research and Quality. Available at: http:// effectivehealthcare. ahrq.gov/repFiles/AnalgesicsFinal.pdf [Last accessed 29 Jun 2010]
14. Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007;115:1634-42 (Pubitemid 46648649)
15. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 Expert Consensus Document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008;118:1894-909
16. Chan FKL, Abraham NS, Scheiman JM, et al. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the first international working party on gastrointestinal and cardiovascular effects of nonsteroidal anti-inflammatory drugs and anti-platelet agents. Am J Gastroenterol 2008;103:2908-18
17. Lanza FL, Chan FK, Quigley EMM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009;104:728-38
18. Scheiman JM, Fendrick AM. Summing the risk of NSAID therapy. Lancet 2007;369:1580-1 (Pubitemid 46710106)
19. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8
20. BresalierRS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102 (Pubitemid 40365350)
21. Jenkins J, Seligman P. Memorandum: analysis and recommendations for Agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk. FDA NDA files 2005:20-998
22. Merck & Co. I. Merck Announces Voluntary Worldwide Withdrawal of VIOXX. Available at: http://www.merck.com/newsroom/vioxx/pdf/vioxx-press-relea- se-final.pdf [Last accessed 11 Dec 2009]
23. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332:1302-8
24. Abraham NS, El-Serag HB, Johnson ML, et al. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology 2005;129:1171-8 (Pubitemid 41446857)
25. Goldstein JL, Howard KB, Walton SM, et al. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. Clin Gastroenterol Hepatol 2006;4:1337-45
26. Sturkenboom MCJM, Burke TA, Tangelder MJD, et al. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2003;18:1137-47 (Pubitemid 38021600)
27. van Soest EM, Sturkenboom MCJM, Dieleman JP, et al. Adherence to gastro-protection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther 2007;26:265-75 (Pubitemid 46985490)
28. Miner Jr P, Plachetka J, Orlemans E, et al. Clinical trial: evaluation of gastric acid suppression with three doses of immediate-release esomeprazole in the fixed-dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric-coated esomeprazole 20 mg: a randomised, open-label, Phase I study in healthy volunteers. Aliment Pharmacol Ther 2010;32:414-24
29. Goldstein JL, Hochberg MC, Fort JG, et al. Clinical trial: incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone. Aliment Pharmacol Ther 2010;32:401-13
30. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986;29:1039-49
31. Bellamy N. WOMAC: a 20-year experiential review of a patient-centered self-reported health status questionnaire. J Rheumatol 2002;29:2473-6 (Pubitemid 35416947)
32. Moskowitz RW, Sunshine A, Brugger A, et al. American pain society pain questionnaire and other pain measures in the assessment of osteoarthritis pain: a pooled analysis of three celecoxib pivotal studies. Am J Ther 2003;10:12-20
33. Pincus T. A multidimensional health assessment questionnaire (MDHAQ) for all patients with rheumatic diseases to complete at all visits in standard clinical care. Bull NYU Hosp Jt Dis 2007;65:150-60 (Pubitemid 350291162)
34. Dougados M, Leclaire P, van der Heijde D, et al. Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative. Osteoarthritis Cartilage 2000;8:395-403 (Pubitemid 32000962)
35. Pham T, van der Heijde D, Lassere M, et al. Outcome variables for osteoarthritis clinical trials: the OMERACT-OARSI set of responder criteria. J Rheumatol 2003;30:1648-54 (Pubitemid 36835471)
36. Bingham III CO, Sebba Al, Rubin BR, et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford) 2007;46:496-507 (Pubitemid 46344665)
37. Bensen WG, Fiechtner JJ, McMillen Jl, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999;74:1095-105 (Pubitemid 30243242)
38. Kivitz AJ, Moskowitz RW, Woods E, et al. Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. J Int Med Res 2001;29:467-79 (Pubitemid 34036826)
39. Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 2006;119:255-66 (Pubitemid 43255067)
40. Cannon GW, Caldwell JR, Holt P, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. Arthritis Rheum 2000;43:978-87 (Pubitemid 30368173)
41. Gibofsky A, Williams GW, McKenna F, et al. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial. Arthritis Rheum 2003;48:3102-11 (Pubitemid 37409321)
42. CleggDO, RedaDJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006;354:795-808 (Pubitemid 43290918)
43. Lehmann R, Brzosko M, Kopsa P, et al. Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib. Curr Med Res Opin 2005;21:517-26 (Pubitemid 40676103)
44. Zhang W, Robertson J, Jones AC, et al. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis 2008;67:1716-23
45. Goldstein JL, Hochberg MC, Fort JG, et al. PN400 significantly reduces the incidence of gastric ulcers compared with enteric-coated naproxen in patients requiring chronic NSAID therapy regardless of low-dose aspirin use: results from two prospective, randomized controlled trials. Arthritis Rheum 2009;60(Suppl. 10):S314
46. Goldstein JL, Hochberg MC, Fort JG, et al. PN400 significantly improved upper gastrointestinal tolerability compared with enteric-coated naproxen alone in patients requiring chronic NSAID therapy: results from two prospective, randomized controlled trials. Am J Gastroenterol 2009; 104(Suppl. 3):S50